Ocugen Stock: Bull vs. Bear
When it comes to contentious stocks, Ocugen (NASDAQ: OCGN) is likely one of the market's leaders. The company is trying to commercialize its coronavirus vaccine candidate and it also boasts long-term growth potential stemming from its group of gene therapies in development for ocular disorders. It's easy to see why there's so much interest in its worthiness as an investment.
With a market cap of only $1.6 billion, it could have a massive amount of room to run. Let's take a look at one argument in favor of buying Ocugen stock and one argument against it to get a better sense of whether it'd be a good pick for your portfolio.
Image source: Getty Images.
Source Fool.com
